In accord with ASX requirements, Imagion Biosystems has lodged “Appendix 4C, Quarterly report for entities subject to Listing Rule 4.7B” for the Quarter ended 30 September 2017.
View Appendix 4C for Q3, 2017.
Imagion Initiates Manufacturing of MagSense® Drug for Phase 2 Clinical Study on HER2+ Breast Cancer
February 19, 2025
MELBOURNE – Imagion Biosystems (Company) (ASX : IBX), a company dedicated to improving healthcare outcomes through the early detection of cancer, is pleased to announce